{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-021850","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.386726+00:00","generated_at":"2026-06-06T11:15:23.296972+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Inhibikase signs $5.66M ATM equity distribution agreement with H.C. Wainwright","bullets":["Entered into ATM equity offering agreement with H.C. Wainwright for up to $5,659,255 of common stock.","Agent receives 3.0% commission on gross proceeds; company reimburses up to $50k initial legal fees plus $2.5k quarterly.","Sales made under existing effective S-3 shelf registration statement (File No. 333-262551) at market prices.","Company has no obligation to sell shares and may suspend or terminate the agreement at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-021850","json":"https://secwatch.observer/filing/0001193125-24-021850.json","markdown":"https://secwatch.observer/filing/0001193125-24-021850.md","text":"https://secwatch.observer/filing/0001193125-24-021850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/0001193125-24-021850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/d769675d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:15:23.296972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2949364f91741e573b82f80f88cb572e2b4068ec","claim":"Inhibikase Therapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $5,659,255 (effective 2024-02-01).","evidence_excerpt":"On February 1, 2024, Inhibikase Therapeutics, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with H.C. Wainwright & Co., LLC, as sales agent (the “ Agent ”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, par value $0.001 per share, in an aggregate offering price of up to $5,659,255 (the “ Shares ”) through the Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/0001193125-24-021850-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"aggregate offering price of up to $5,659,255"},{"label":"Effective","value":"2024-02-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}